197 related articles for article (PubMed ID: 24482900)
21. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
Terrill KR; Lemons RS; Goldsby RE
J Pediatr Hematol Oncol; 2003 Nov; 25(11):864-7. PubMed ID: 14608195
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters: A retrospective cohort study.
Van Hulle F; Bonkain F; De Clerck D; Aerden D; Vanwijn I; Tielemans C; Wissing KM
J Vasc Access; 2019 Jan; 20(1):60-69. PubMed ID: 29893163
[TBL] [Abstract][Full Text] [Related]
23. Intravenous catheter declotting: same outcomes with lower dose urokinase?
Juvé ME
J Infus Nurs; 2003; 26(4):245-51. PubMed ID: 12869858
[TBL] [Abstract][Full Text] [Related]
24. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
[TBL] [Abstract][Full Text] [Related]
25. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
[TBL] [Abstract][Full Text] [Related]
26. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.
Haire WD; Deitcher SR; Mullane KM; Jaff MR; Firszt CM; Schulz GA; Schuerr DM; Schwartz LB; Mouginis TL; Barton RP
Thromb Haemost; 2004 Sep; 92(3):575-82. PubMed ID: 15351854
[TBL] [Abstract][Full Text] [Related]
27. Stability and sterility of recombinant tissue plasminogen activator at -30 degrees C.
Wiernikowski JT; Crowther M; Clase CM; Ingram A; Andrew M; Chan AK
Lancet; 2000 Jun; 355(9222):2221-2. PubMed ID: 10881901
[TBL] [Abstract][Full Text] [Related]
28. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
[TBL] [Abstract][Full Text] [Related]
29. Reteplase for clearance of occluded venous catheters.
Owens L
Am J Health Syst Pharm; 2002 Sep; 59(17):1638-40. PubMed ID: 12224345
[No Abstract] [Full Text] [Related]
30. Nurse's guide to understanding and treating thrombotic occlusion of central venous access devices.
McKnight S
Medsurg Nurs; 2004 Dec; 13(6):377-82. PubMed ID: 15714740
[TBL] [Abstract][Full Text] [Related]
31. Thrombolytics for occluded catheters.
Horne MK
Crit Care Med; 2004 Oct; 32(10):2146-7. PubMed ID: 15483427
[No Abstract] [Full Text] [Related]
32. Thrombosis of tunneled-cuffed hemodialysis catheters: treatment with high-dose urokinase lock therapy.
Donati G; Colì L; Cianciolo G; La Manna G; Cuna V; Montanari M; Gozzetti F; Stefoni S
Artif Organs; 2012 Jan; 36(1):21-8. PubMed ID: 21848863
[TBL] [Abstract][Full Text] [Related]
33. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
[TBL] [Abstract][Full Text] [Related]
34. Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials.
Kethireddy S; Safdar N
J Vasc Access; 2008; 9(1):51-7. PubMed ID: 18379981
[TBL] [Abstract][Full Text] [Related]
35. Prospective Audit to Study urokinaSe use to restore Patency in Occluded centRal venous caTheters in haematology and oncology patients (PASSPORT 2).
Kumwenda MJ; Dougherty L; Jackson A; Hill S
J Vasc Access; 2021 Jul; 22(4):568-574. PubMed ID: 32867568
[TBL] [Abstract][Full Text] [Related]
36. TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters.
Gabrail N; Sandler E; Charu V; Anas N; Lim E; Blaney M; Ashby M; Gillespie BS; Begelman SM
J Vasc Interv Radiol; 2010 Dec; 21(12):1852-8. PubMed ID: 21111365
[TBL] [Abstract][Full Text] [Related]
37. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters.
Atkinson JB; Bagnall HA; Gomperts E
JPEN J Parenter Enteral Nutr; 1990; 14(3):310-1. PubMed ID: 2112648
[TBL] [Abstract][Full Text] [Related]
38. Techniques in dosing for thrombolysis of occluded central venous catheters.
Haire WD
Tech Vasc Interv Radiol; 2001 Jun; 4(2):127-30. PubMed ID: 11981800
[TBL] [Abstract][Full Text] [Related]
39. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
[TBL] [Abstract][Full Text] [Related]
40. Low-molecular-weight heparin and calcium heparin in thrombosis prophylaxis in patients with percutaneous arterial and venous ports for colorectal liver metastases.
Zanon C; Bortolini M; Chiappino I
Tumori; 2005; 91(6):477-80. PubMed ID: 16457145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
